ArticleScientific reports2025
Development of Epstein Barr virus biosensor by mimicking its infection mechanism for early detection of multiple sclerosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanoparticles Based Therapeutic Approaches in Oncogenic Viral Infections: A Review.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Given the established link between Epstein-Barr virus (EBV) and multiple sclerosis, the early and asymptomatic detection of EBV has become increasingly important. In this study, we developed an impedimetric EBV biosensor designed for practical and early screening, based on mimicking the virus's natural infection mechanism. To achieve this, the B cell surface protein CD21-serving as the host receptor-was immobilized onto a carbon screen-printed electrode. The interaction between CD21 and the EBV surface glycoprotein gp350 was monitored using electrochemical impedance spectroscopy. Following the optimization of experimental parameters, the biosensor's analytical performance was evaluated. It exhibited a linear detection range from 5 to 100 ng/mL, with a limit of detection of 0.0074 ng/mL, a limit of quantification of 0.022 ng/mL, and a relative standard deviation of 1.34%. The optimized biosensor was then tested using 1:100 diluted saliva samples collected from healthy individuals, yielding highly promising results that support its potential for real-world applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.